Luspatercept clinical trials
Also written ACE-536, Reblozyl and BMS-986346.
How each study uses luspatercept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the luspatercept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 8 Nov 2019 · REBLOZYL · BLA 761136 (FDA, Drugs@FDA)
- European Union
- 25 Jun 2020 · Reblozyl · EMEA/H/C/004444 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2026 (10)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 7 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 29
Celgene (10) · Bristol-Myers Squibb (5) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (5) · Institute of Hematology & Blood Diseases Hospital, China (3) · Peking Union Medical College Hospital (2) · Nanfang Hospital, Southern Medical University (2) · M.D. Anderson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Pacritinib (1) · Momelotinib (1) · Azacitidine (1) · Busulfan (1) · Cytarabine (1) · Daunorubicin (1) · Decitabine and cedazuridine drug combination (1) · CA-4948 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7, 1 in phase 3
Studies that test luspatercept, phase 3 first.
- Jun 2027Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic SyndromesPhase 3 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026Luspatercept for CIA in AMLPhase 1/2 · Guangdong Second Provincial General Hospital
- Feb 2027Luspatercept for Clonal Cytopenias of Uncertain SignificancePhase 2 · Weill Medical College of Cornell University
- Mar 2027Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisPhase 2 · GlaxoSmithKline
- May 2027Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical StudyNot applicable · The First Affiliated Hospital of Zhejiang Chinese Medical University
- Jun 2027The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCTPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Jul 2027A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaPhase 2 · Bristol-Myers Squibb
Studies
Open first, then newest update. How each study uses luspatercept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- Luspatercept in Patients Affected With Rare Inherited AnemiasRecruitingPhase 2EuroBloodNet AssociationNCT07331818Written as ReblozylHow we know
- Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and ThrombocytopeniaNot yet recruitingPhase 2Case Comprehensive Cancer CenterNCT07936201Written as LuspaterceptHow we know
- Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisRecruitingPhase 2GlaxoSmithKlineNCT06517875Written as LuspaterceptHow we know
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as LuspaterceptHow we know
- Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic SyndromesNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07894861Written as LuspaterceptHow we know
- A Study of Luspatercept in People With AnemiaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07725497Written as LuspaterceptHow we know
- Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) PatientsNot yet recruitingPhase 4University Hospital, GrenobleNCT07830004Written as LuspaterceptHow we know
- Luspatercept + Darbepoetin in MDSRecruitingPhase 2Yale UniversityNCT07096297Written as LuspaterceptHow we know
- Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingPhase 2CelgeneNCT04143724Written as ACE-536How we know
- A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsRecruitingPhase 3CelgeneNCT04064060Written as LuspaterceptHow we know
- Luspatercept for CIA in AMLRecruitingPhase 1/2Guangdong Second Provincial General HospitalNCT07663864Written as Luspatercept Injectable ProductHow we know
- Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological MalignanciesNot yet recruitingPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT07636486Written as LuspaterceptHow we know
- Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe MyelofibrosisNot yet recruitingPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT07539779Written as LuspaterceptHow we know
- Luspatercept for Clonal Cytopenias of Uncertain SignificanceRecruitingPhase 2Weill Medical College of Cornell UniversityNCT06788691Written as LuspaterceptHow we know
- The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCTNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07450313Written as LuspaterceptHow we know
- Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)RecruitingPhase 1/2Zhujiang HospitalNCT07362095Written as LuspaterceptHow we know
- Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT PatientsRecruitingPhase 2Rongrong LiuNCT07338344Written as Luspatercept combined with low-dose thalidomideHow we know
- Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical StudyNot yet recruitingNot applicableThe First Affiliated Hospital of Zhejiang Chinese Medical UniversityNCT06964971Written as LuspaterceptHow we know
- Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TDRecruitingPhase 2Associazione Qol-oneNCT05924100Written as Luspatercept Injection [Reblozyl]How we know
- The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic SyndromesRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05925504Written as LuspaterceptHow we know
See all 50 studies that test luspatercept →
Given beside what is tested · 4 — luspatercept is usual care or a partner of the new treatment
- Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and AnemiaNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07938580Written as LuspaterceptHow we know
- Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESARecruitingPhase 1/2Groupe Francophone des MyelodysplasiesNCT05181735Written as Luspatercept Injection [Reblozyl]How we know
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07463820Written as LuspaterceptHow we know
- Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAAWithdrawnPhase 4Peking Union Medical College HospitalNCT06424639Written as LuspaterceptHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- Luspatercept in Patients Affected With Rare Inherited AnemiasNov 17, 2026NCT07331818
Newly registered2
Codes
What other systems call luspatercept · ClinicalTrials.gg INT000734
- MeSH (NLM) C000621232luspaterceptConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) AQK7UBA1LSLUSPATERCEPTConfirmed FDA, NLM, Wikidata
- RxNorm 2262544Confirmed FDA, Wikidata
- Wikidata Q30314143luspaterceptConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C104012LuspaterceptOne source FDA
- DrugBank DB12281One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621232 | luspatercept | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | AQK7UBA1LS | LUSPATERCEPT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2262544 | — | Confirmed FDA, Wikidata |
| Wikidata | Q30314143 | luspatercept | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C104012 | Luspatercept | One source FDA |
| DrugBank | DB12281 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.